Clinical Trial Detail

NCT ID NCT03969446
Title Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Decitabine + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.